SB525334
Modify Date: 2024-01-08 17:10:48
SB525334 structure
|
Common Name | SB525334 | ||
|---|---|---|---|---|
| CAS Number | 356559-20-1 | Molecular Weight | 343.425 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 540.5±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H21N5 | Melting Point | 159 °C | |
| MSDS | Chinese USA | Flash Point | 238.6±21.7 °C | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of SB525334SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM. |
| Name | 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline |
|---|---|
| Synonym | More Synonyms |
| Description | SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 540.5±45.0 °C at 760 mmHg |
| Melting Point | 159 °C |
| Molecular Formula | C21H21N5 |
| Molecular Weight | 343.425 |
| Flash Point | 238.6±21.7 °C |
| Exact Mass | 343.179688 |
| PSA | 67.35000 |
| LogP | 4.05 |
| Appearance of Characters | yellow |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.636 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: ≥20mg/mL |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301-H315-H319-H335-H413 |
| Precautionary Statements | P261-P301 + P310-P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn |
| Risk Phrases | 22-36/37/38 |
| Safety Phrases | 26 |
| RIDADR | UN 2811 6.1/PG 3 |
| Hazard Class | 6.1 |
| HS Code | 2934999090 |
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|
Mesenchymal activin-A overcomes defective human trisomy 21 trophoblast fusion.
Endocrinology 152 , 5017-28, (2011) Placental development is markedly abnormal in trisomy 21 (T21) pregnancies. We hypothesized that abnormal paracrine cross talk between the fetal mesenchymal core and the trophoblast might be involved ... |
|
|
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
J. Pharmacol. Exp. Ther. 313 , 943-951, (2005) SB-525334 (6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline) has been characterized as a potent and selective inhibitor of the transforming growth factor-beta1 (TGF-beta1) recep... |
|
|
Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline
Am. J. Pathol. 174(2) , 380-9, (2009) Mutations in the gene for the transforming growth factor (TGF)-β superfamily receptor, bone morphogenetic protein receptor II, underlie heritable forms of pulmonary arterial hypertension (PAH). Aberra... |
| 6-[2-tert-Butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl]quinoxaline |
| 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline |
| SB 525334 |
| Quinoxaline, 6-[2-(1,1-dimethylethyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]- |
| 6-[2-(2-Methyl-2-propanyl)-5-(6-methyl-2-pyridinyl)-1H-imidazol-4-yl]quinoxaline |
| 6-(2-tert-butyl-4-(6-methylpyridin-2-yl)-1H-imidazol-5-yl)quinoxaline |
| S1476_Selleck |
| SB525334 |
| 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline |
| 6-[2-tert-butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline |